Fierce Biotech19h
Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail'
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
BioPharma Dive17h
How biotech and pharma teams are reaching LPI ahead of schedule
With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...
Clinical Trials Arena on MSN19h
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial
The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.